Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioLife SolutionsBLFS +4.32%73 Intrinsic Value: Projected FCF is $5.60 as of Aug. 19, 2026, which is 4% above its 10-year median of 5.37. GuruFocus rates BLFS with a GF Score™ of 73/100 and a GF Value™ of $30.08 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 402 Medical Devices & Instruments companies, BioLife Solutions ranks worse than 92.04% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-08-19), BioLife Solutions's Intrinsic Value: Projected FCF is $5.60. The stock price of BioLife Solutions is $36.47. Therefore, BioLife Solutions's Price-to-Intrinsic-Value-Projected-FCF of today is 6.5.
The historical rank and industry rank for BioLife Solutions's Intrinsic Value: Projected FCF or its related term are showing as below:
BLFS'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 2.31 Med: 5.37 Max: 29.66
Current: 6.51
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of BioLife Solutions was 29.66. The lowest was 2.31. And the median was 5.37.
BLFS's Price-to-Projected-FCF is ranked worse than 92.04% of 402
companies
in the Medical Devices & Instruments industry
Industry Median: 1.5
vs BLFS: 6.51
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
BioLife Solutions's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
36.47
/
5.5982924122928
=
6.51
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioLife Solutions Intrinsic Value: Projected FCF Related Terms
BioLife Solutions Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for BioLife Solutions's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLFS vs AZTA, KMTS, STAA: Intrinsic Value: Projected FCF Comparison
For the Medical Instruments & Supplies subindustry, BioLife Solutions's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLife Solutions Price-to-Projected-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where BioLife Solutions's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $5.60 mean?
BioLife Solutions (BLFS) has a Intrinsic Value: Projected FCF of $5.60 as of Aug. 19, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on BioLife Solutions and its competitors. This is near median its historical median of 5.37. Over the past decade, BioLife Solutions' Intrinsic Value: Projected FCF has ranged from 2.31 to 29.66. According to the industry distribution chart, BioLife Solutions ranks #370 out of 402 companies in the Medical Devices & Instruments industry, placing it in the top 92%.
Is BioLife Solutions' Intrinsic Value: Projected FCF too high?
BioLife Solutions' current Intrinsic Value: Projected FCF of $5.60 is near median its 10-year median of 5.37. Over the past 10 years, this metric has ranged from a low of 2.31 to a high of 29.66. The Medical Devices & Instruments industry median Intrinsic Value: Projected FCF is 1.50. BioLife Solutions' value of $5.60 is 273.3% above this industry median. Based on the distribution chart, BioLife Solutions ranks #370 out of 402 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, BioLife Solutions has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioLife Solutions' Intrinsic Value: Projected FCF compare to AZTA and KMTS?
According to the Medical Devices & Instruments industry distribution chart, BioLife Solutions ranks #370 out of 402 companies for Intrinsic Value: Projected FCF. This places BioLife Solutions in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.50. BioLife Solutions' value of $5.60 is 273.3% above this benchmark. Historically, BioLife Solutions' own Intrinsic Value: Projected FCF has ranged from 2.31 to 29.66 over the past decade. While the company's 10-year median is 5.37 vs. the industry median of 1.50, BioLife Solutions has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Medical Devices & Instruments company?
The median Intrinsic Value: Projected FCF among Medical Devices & Instruments companies is 1.50, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioLife Solutions's current Intrinsic Value: Projected FCF of $5.60 is 273.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on BioLife Solutions and its competitors. For the Medical Devices & Instruments industry, the median Intrinsic Value: Projected FCF is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLife Solutions's current Intrinsic Value: Projected FCF is $5.60, which is near median its own 10-year median of 5.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLife Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioLife Solutions (BLFS) is currently considered Modestly Overvalued. The stock's GF Value™ is $30.08, compared to a current price of $36.47 — trading 21.2% above its estimated fair value. The current Intrinsic Value: Projected FCF is $5.60, which is near median its 10-year median of 5.37 and 273.3% above the Medical Devices & Instruments industry median of 1.50. BioLife Solutions' overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For BioLife Solutions (BLFS), the current Intrinsic Value: Projected FCF is $5.60 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioLife Solutions (BLFS) Overvalued in 2026?
Based on GuruFocus' analysis, BioLife Solutions stock appears to be overvalued.
The current stock price of $36.47 is trading 21.2% above its estimated GF Value™ of $30.08.
GuruFocus considers BioLife Solutions to be Modestly Overvalued.
Key valuation signals for BLFS:
Intrinsic Value: Projected FCF: $5.60 (near median its 10-year median of 5.37)
GF Value™: $30.08 vs. price of $36.47 (21.2% above fair value)
Industry Position: 273.3% above the Medical Devices & Instruments median (#370 of 402)
No single metric tells the full story. See the BLFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
73GF Score
Get the complete analysis for BLFS
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLFS has been successfully added to your 
